OssDsign: While adding potential, acquisition prompts questions on financing

Research Update

2020-12-10

07:20

Redeye raises its long-term estimates and valuation somewhat following OssDsign’s broadening towards synthetic bone grafts for spinal fusion through the acquisition of Sirakoss. We have a relatively conservative stance on the new product’s sales potential at present, though increased clinical validation and demonstrated commercial interest could prompt a reassessment further out.

OB

Oscar Bergman

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.